Sweden's DexTech Q3 loss widens, OsteoDex drug study shows favorable safety profile

Dextech Medical AB

05/05/2026 10:39

Overview

Sweden drug developer's fiscal Q3 net sales were SEK 0 mln, unchanged from last year

Fiscal Q3 operating loss widened and EPS declined from a year earlier

Lead drug OsteoDex showed favorable safety and stable disease in majority of patients

Outlook

DexTech expects formal OsteoDex study report completion in Q3 2026, later than previously announced

Company says working capital is sufficient to finance operations until end of 2028

Result Drivers

CLINICAL TRIAL PROGRESS - Majority of patients in OsteoDex study transitioned from progressive to stable disease and drug showed favorable safety profile

Company press release: ID:nWkr8skPY

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
SEK 0
Q3 EPS
-SEK 0.09
Q3 Operating Profit
-SEK 1.70 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)